Physician profile
Daniela Olivera-Parente
NPI 1114439726
$2,788.89
in general payments reported to CMS, 2019-2025
28 companies · $795 in 2025
The $795 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.16 · 2022: $640 · 2023: $748 · 2024: $594 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $581.33 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $479.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $326.39 | 2023-2025 | |
| Exact Sciences Corporation | $238.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $218.11 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $149.08 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.60 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $74.37 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $68.08 | 2022-2024 | Quviviq |
| Abbvie INC. | $66.15 | 2023-2024 | |
| Sonex Health, INC. | $53.17 | 2025 | Sx-One Microknife |
| Eisai INC. | $41.73 | 2025 | |
| Pfizer INC. | $38.91 | 2023 | |
| Dexcom, INC. | $37.37 | 2024-2025 | Dexcom G6 Transmitter |
| Phadia US INC. | $36.40 | 2022-2024 | Immunocap |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $34.44 | 2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $26.79 | 2023 | Rexulti |
| Almatica Pharma LLC | $22.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.90 | 2022 | |
| Mannkind Corporation | $20.62 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.00 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $15.93 | 2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $15.33 | 2025 | Airsupra |
| Tms Neurohealth Centers INC. | $15.14 | 2025 | Tms Neurohealth Centers INC. |
| Boston Scientific Corporation | $14.98 | 2023 | Watchman Flx |
| Medicure Pharma INC. | $13.85 | 2025 | Zypitamag |
| Amneal Pharmaceuticals LLC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Olivera-Parente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.